Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
This is a phase II study to evaluate the efficacy of ibrutinib in combination with bortezomib in in MCL (mantle cell lymphoma) patients who relapsed on single agent ibrutinib.
Mantle Cell Lymphoma
DRUG: Bortezomib|DRUG: Ibrutinib
The proportion of participants that respond to treatment at 6 months, The primary endpoint is overall response rate (ORR). Participants will be evaluated for response based on the Lugano criteria., 6 Months
Overall survival time, Patients will be followed for survival until death or up to 10 years., Up to 10 Years|Progression free survival time, Progression will be determined using the Lugano criteria. Patients will be followed for survival until death or up to 10 years., Up to 10 Years|Best overall response, Participants will be evaluated for response based on the Lugano criteria. From the start of the study treatment until the disease progression/recurrence or up to 10 years., Up to 10 Years|Rate of complete response, Participants will be evaluated for response based on the Lugano criteria. The percentage of participants who achieve CR after treatment., Up to 10 Years|Time to progression, Progression will be determined using the Lugano criteria., Up to 10 Years
This is a phase II study to evaluate the efficacy of ibrutinib in combination with bortezomib in in MCL (mantle cell lymphoma) patients who relapsed on single agent ibrutinib.